NxStage Medical (NXTM) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance
May 6, 2015 7:59 AM EDTLAWRENCE, Mass., May 6, 2015 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported first quarter financial results that exceed the top end of its guidance range.
Revenue for the first quarter of 2015 increased 10 percent to $79.5 million, compared with revenue of $72.2 million for the first quarter of 2014. The Company's revenue guidance range for the first quarter was $77.5 million to $78.5 million. The increase was driven by outperformance in the System One segment which consists of... More
